PMID- 31887838
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20200108
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 59
IP  - 1
DP  - 2020 Jan 1
TI  - [Matrix metalloproteinase-3 in patients with systemic lupus erythematosus and its 
      significance in differentiating disease activity from pulmonary infections].
PG  - 58-61
LID - 10.3760/cma.j.issn.0578-1426.2020.01.010 [doi]
AB  - The purpose of this study is to investigate the matrix metalloproteinase-3 
      (MMP-3) levels in patients with systemic lupus erythematosus (SLE) and its 
      significance in identifying disease activity and pulmonary infections. A total of 
      122 SLE patients were enrolled, including 21 with pulmonary infections, 16 with 
      arthritis, 26 with nephritis, 10 with vasculitis, and 23 healthy controls. Serum 
      MMP-3, C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (HPT) 
      levels were measured in all subjects. The results showed that the levels of MMP-3 
      in SLE combined with pulmonary infections [(230.10+/-44.92) mug/L], arthritis 
      [(140.20+/-20.76) mug/L], nephritis [(155.40+/-23.36) mug/L] were higher than those in 
      SLE only [(91.74+/-10.47) mug/L]. The levels of MMP-3 [(210.30+/-45.71) mug/L], CRP 
      [(12.11+/-5.21) mg/L], HPT [(1.57+/-0.23) g/L] in active SLE combined with pulmonary 
      infections were higher than those inactive SLE without pulmonary infections 
      including MMP-3 [(124.00+/-15.22) mug/L], CRP [(7.76+/-2.96) mg/L], HPT [(0.89+/-0.09) 
      g/L]. The levels of CRP [(10.03+/-2.70) mg/L], SAA [(89.22+/-36.77) mg/L] in active 
      SLE with pulmonary infections and CRP[(7.76+/-2.96) mg/L], SAA [(60.22+/-19.7) mg/L] 
      in active SLE without pulmonary infections were higher than CRP [(1.90+/-0.39) 
      mg/L], SAA [(17.60+/-3.89) mg/L] in stable SLE with pulmonary infections. It 
      suggests that the levels of CRP and SAA are elevated in active SLE with pulmonary 
      infections. Serum MMP-3 in combination with CRP may assist in differentiating 
      from SLE pulmonary infections.
FAU - Li, M Y
AU  - Li MY
AD  - Department of Rheumatology and Immunology, Subsidiary Hospital, Southwestern 
      Medical University, Luzhou, Sichuan Province 646000, China.
FAU - Bai, Y Q
AU  - Bai YQ
AD  - Department of Rheumatology and Immunology, West China Hospital, Sichuan 
      University, Chengdu 610041, China.
FAU - Liu, Y
AU  - Liu Y
AD  - Department of Rheumatology and Immunology, Subsidiary Hospital, Southwestern 
      Medical University, Luzhou, Sichuan Province 646000, China; Department of 
      Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu 
      610041, China.
LA  - chi
GR  - 2016YFC0906201/National Natural Science Foundation of China/
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - *Arthritis
MH  - C-Reactive Protein/metabolism
MH  - Case-Control Studies
MH  - Humans
MH  - *Infections
MH  - *Lupus Erythematosus, Systemic
MH  - Matrix Metalloproteinase 3/*metabolism
OTO - NOTNLM
OT  - C-reactive protein
OT  - Lupus erythematosus, systemic
OT  - Matrix metalloproteinase 3
OT  - Pulmonary infection
EDAT- 2019/12/31 06:00
MHDA- 2020/01/07 06:00
CRDT- 2019/12/31 06:00
PHST- 2019/12/31 06:00 [entrez]
PHST- 2019/12/31 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
AID - 10.3760/cma.j.issn.0578-1426.2020.01.010 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):58-61. doi: 
      10.3760/cma.j.issn.0578-1426.2020.01.010.